Search

Your search keyword '"Niegisch, Günter"' showing total 444 results
Start Over Author "Niegisch, Günter"
444 results on '"Niegisch, Günter"'

101. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Petrylak, Daniel P, primary, de Wit, Ronald, additional, Chi, Kim N, additional, Drakaki, Alexandra, additional, Sternberg, Cora N, additional, Nishiyama, Hiroyuki, additional, Castellano, Daniel, additional, Hussain, Syed A, additional, Fléchon, Aude, additional, Bamias, Aristotelis, additional, Yu, Evan Y, additional, van der Heijden, Michiel S, additional, Matsubara, Nobuaki, additional, Alekseev, Boris, additional, Necchi, Andrea, additional, Géczi, Lajos, additional, Ou, Yen-Chuan, additional, Coskun, Hasan Senol, additional, Su, Wen-Pin, additional, Bedke, Jens, additional, Gakis, Georgios, additional, Percent, Ivor J, additional, Lee, Jae-Lyun, additional, Tucci, Marcello, additional, Semenov, Andrey, additional, Laestadius, Fredrik, additional, Peer, Avivit, additional, Tortora, Giampaolo, additional, Safina, Sufia, additional, Garcia del Muro, Xavier, additional, Rodriguez-Vida, Alejo, additional, Cicin, Irfan, additional, Harputluoglu, Hakan, additional, Tagawa, Scott T, additional, Vaishampayan, Ulka, additional, Aragon-Ching, Jeanny B, additional, Hamid, Oday, additional, Liepa, Astra M, additional, Wijayawardana, Sameera, additional, Russo, Francesca, additional, Walgren, Richard A, additional, Zimmermann, Annamaria H, additional, Hozak, Rebecca R, additional, Bell-McGuinn, Katherine M, additional, Powles, Thomas, additional, Wong, Suet-Lai Shirley, additional, Tan, Thean Hsiang, additional, Hovey, Elizabeth Jane, additional, Clay, Timothy Dudley, additional, Wan Ng, Siobhan Su, additional, Rutten, Annemie, additional, Machiels, Jean-Pascal, additional, Dumez, Herlinde, additional, Cheng, Susanna Yee-Shan, additional, Ferrario, Cristiano, additional, Sengeloev, Lisa, additional, Jensen, Niels Viggo, additional, Thibault, Constance, additional, Laguerre, Brigitte, additional, Joly, Florence, additional, Culine, Stéphane, additional, Becht, Catherine, additional, Niegisch, Günter, additional, Stöckle, Michael, additional, Grimm, Marc-Oliver, additional, Schwentner, Christina A, additional, Schultze-Seemann, Wolfgang, additional, Kalofonos, Haralambos, additional, Mavroudis, Dimitrios, additional, Papandreou, Christos, additional, Karavasilis, Vasilis, additional, Révész, Janos, additional, Rosenbaum, Eli, additional, Leibowitz-Amit, Raya, additional, Kejzman, Daniel, additional, Sarid, David, additional, Scagliotti, Giorgio Vittorio, additional, Bracarda, Sergio, additional, Massari, Francesco, additional, Osawa, Takahiro, additional, Miyajima, Naoto, additional, Shinohara, Nobuo, additional, Fukuta, Fumimasa, additional, Ohyama, Chikara, additional, Obara, Wataru, additional, Yamashita, Shinichi, additional, Tomita, Yoshihiko, additional, Kawai, Koji, additional, Fukasawa, Satoshi, additional, Oyama, Masafumi, additional, Yonese, Junji, additional, Nagata, Masayoshi, additional, Uemura, Motohide, additional, Nishimura, Kazuo, additional, Kawakita, Mutsushi, additional, Tsunemori, Hiroyuki, additional, Hashine, Katsuyoshi, additional, Inokuchi, Junichi, additional, Yokomizo, Akira, additional, Nagamori, Satoshi, additional, Lee, Hyo Jin, additional, Park, Se Hoon, additional, Rha, Sun Young, additional, Kim, Yu Jung, additional, Lee, Yun-Gyoo, additional, Vazquez Cortés, Leticia, additional, Lorena Urzua Flores, Claudia, additional, Blaisse, Reinoud J.B., additional, Erdkamp, Fransiscus L.G., additional, Aarts, Maureen J.B., additional, Wojcik-Tomaszewska, Joanna, additional, Tomczak, Piotr, additional, Sikora-Kupis, Bozena, additional, Schenker, Michael, additional, Herzal, Alina Amalia, additional, Udrea, Anghel Adrian, additional, Karlov, Petr, additional, Fomkin, Roman, additional, Gajate Borau, Pablo, additional, Grande, Enrique, additional, Delgado Mignorance, Juan Ignacio, additional, Su, Yu-Li, additional, Li, Jian-Ri, additional, Lin, Chien-Liang, additional, Lin, Chia-Chi, additional, Yeh, Su-Peng, additional, Erman, Mustafa, additional, Urun, Yuksel, additional, Golovko, Yuriy, additional, Bondarenko, Igor, additional, Sinielnikov, Ivan, additional, Crabb, Simon J., additional, Syndikus, Isabel, additional, Huddart, Robert, additional, Sundar, Santhanam, additional, Chowdhury, Simon, additional, Sarwar, Naveed, additional, Flaig, Thomas W., additional, Pan, Chong Xian, additional, Schwarz, James K., additional, Cultrera, Jennifer Lyn, additional, Acs, Peter Istvan, additional, Hainsworth, John D., additional, Herms, Benjamin T., additional, Lawler, William Eyre, additional, and Lowe, Thomas Eugene, additional

Published
2020
Full Text
View/download PDF

104. Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?

Author

Niegisch, Günter, Hulsbergen - van de Kaa, Christina, Ploeg, Martine, Hendricksen, Kees, and Witjes, J. Alfred

Abstract

A second primary tumors of the urethra (urethral recurrence) after radical cystectomy has been reported to be more infrequent in patients with ileal orthotopic (neobladder) compared to incontinent diversions. To investigate whether an altered immunogenic environment of urethral tissue is induced by urethro-ileal anastomosis. Between 10/2008 and 12/2009 urethral biopsies of 19 patients (9 neobladder patients, 10 control patients without urethra-ileal anastomosis) were evaluated by conventional histopathological examination and immunohistochemistry for T- (CD3/CD5, CD4, CD8) and B-cell markers (CD20/22, CD79a, CD138). After semi-quantitative assessment, relative cell fractions (B vs. T cells) and subclasses (T4-helper vs. T8-killer cells vs. B cell clones, plasma cells) in neobladder vs. control patients were studied. Unpaired t-test was used for statistical analysis. Of 19 included patients, 16 were eligible for analysis (7x neobladder, 9x controls). All neobladder patients had undergone cystectomy for UBC. Comparing relative fractions of cells positive for T- and B-cell markers in NB and CO patients, no statistical differences were observed. In 4/7 neobladder patients relative fraction of CD79a positive B-cells was higher than relative fraction of CD3/CD5 positive T-cells (B/T-ratio 1.3). B cells were predominantly CD138 positive plasma cells (5/7 NB patients). Relative B-cell fraction was lower than T-cell fraction in 7/9 control patients (B/T-ratio 0.6). Neither CD 138 positive plasma cells nor CD22 positive B cell clones were predominant. T-helper and CD8 positive T-killer cells were equally distributed in both neobladder (CD4/CD8-ratio: 2.1) and control patients (CD4/CD8-ratio: 1.9). Comparing neobadder and control patients the distribution of B- and T-cells was statistically not different. However, a trend towards an increased presence of B-cells in urethral tissues of NB patients that could become relevant in a larger study might be suggestive for an immunological response induced by connecting urethral and ileal tissue.

Published
2022
Full Text
View/download PDF

106. Additional file 1: of Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Author

Hölscher, Alexander, Schulz, Wolfgang, Pinkerneil, Maria, Niegisch, Günter, and Hoffmann, Michèle

Abstract

Information on primer sequences and antibodies. Sequence information and amplicon sizes for qRT-PCR and ChIP qPCR primers as well as product information and dilution of applied antibodies are given. (PDF 271 kb)

Published
2018
Full Text
View/download PDF

107. Additional file 5: of Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Author

Hölscher, Alexander, Schulz, Wolfgang, Pinkerneil, Maria, Niegisch, Günter, and Hoffmann, Michèle

Subjects
sense organs
Abstract

Data on expression changes of of p57 KIP2 mRNA by combination treatment in UC cells. Relative mRNA expression levels of p57 KIP2 mRNA after single and combined treatment with Romidepsin and JQ1. mRNA levels were measured by qRT-PCR and normalized to the expression of TBP. Fold change compared to DMSO control 48 h after treatment is displayed on the ordinate. (PDF 100 kb)

Published
2018
Full Text
View/download PDF

108. Additional file 2: of Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Author

Hölscher, Alexander, Schulz, Wolfgang, Pinkerneil, Maria, Niegisch, Günter, and Hoffmann, Michèle

Abstract

Data on synergistic effects on cell viability of primary cancer cells by combined treatment with Romidepsin and JQ1. (a), (b) Relative viability of primary cultures 1 and 2 established from primary tumor tissue of two different patients after single or combined treatment for 48 h. Relative viability is displayed on the ordinate in percent of the control cells treated with DMSO. (c) Primary culture 2 was used for an extended dose response curve analysis after 24 h to perform Chou-Talalay calculations (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05). (d) Combination index (CI/Fa) plot for the combination of JQ1 and Romidepsin. Cell viability was measured at five constant dose ratio experimental data points by ATP assay for primary culture 2. CI plots were then generated using CompuSyn software. CI

Published
2018
Full Text
View/download PDF

109. Additional file 7: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Author

Kaletsch, Aline, Pinkerneil, Maria, Hoffmann, Michèle, Vasudevan, Ananda Jaguva, Chenyin Wang, Hansen, Finn, Wiek, Constanze, Hanenberg, Helmut, Gertzen, Christoph, Gohlke, Holger, Kassack, Matthias, Kurz, Thomas, Schulz, Wolfgang, and Niegisch, Günter

Abstract

Figure S5. Expression of HDAC1, HDAC2 and HDAC6 mRNA following treatment of UCCs with 19i or SAHA. Effects of 24 and 48 h treatment with 19i (2 μM), SAHA (2.5 μM) or DMSO as solvent control on mRNA expression of HDAC1, HDAC2 and HDAC6 in VM-CUB1, UM-UC-3 and 639-V cells. All values indicate relative expression compared to a standard for each gene, adjusted to TBP as a reference gene and set as 1 for the solvent control. Significance levels likewise refer to the solvent control (* = p

Published
2018
Full Text
View/download PDF

110. Additional file 4: of Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Author

Hölscher, Alexander, Schulz, Wolfgang, Pinkerneil, Maria, Niegisch, Günter, and Hoffmann, Michèle

Abstract

Data on induction of apoptotic cell death by combined treatment with Romidepsin and JQ1. Induction of apoptotic cell death by combined treatment with Romidepsin and JQ1. Flow cytometric analysis of UCCs with indicated treatment after combined staining with PI and Annexin V. Percentages of viable (lower left), early (lower right), or late (upper right) apoptotic and necrotic (upper left) VM-Cub1 cells subsequent to indicated treatments. (PDF 1052 kb)

Published
2018
Full Text
View/download PDF

111. Additional file 6: of Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

Author

Hölscher, Alexander, Schulz, Wolfgang, Pinkerneil, Maria, Niegisch, Günter, and Hoffmann, Michèle

Abstract

Data on STAT3 activation and expression after combination treatment in UC cells. Phosphorylated and total STAT3 protein was detected by Western blot analysis in four UC cell lines cells after indicated treatment. α-tubulin served as an additional loading control. (PDF 216 kb)

Published
2018
Full Text
View/download PDF

113. Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines

Author

Skowron, Margaretha A., primary, Petzsch, Patrick, additional, Hardt, Karin, additional, Wagner, Nicholas, additional, Beier, Manfred, additional, Stepanow, Stefanie, additional, Drechsler, Matthias, additional, Rieder, Harald, additional, Köhrer, Karl, additional, Niegisch, Günter, additional, Hoffmann, Michèle J., additional, and Schulz, Wolfgang A., additional

Published
2019
Full Text
View/download PDF

114. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

Author

Pederzoli, Filippo, primary, Bandini, Marco, additional, Briganti, Alberto, additional, Plimack, Elizabeth R., additional, Niegisch, Günter, additional, Yu, Evan Y., additional, Bamias, Aristotelis, additional, Agarwal, Neeraj, additional, Sridhar, Srikala S., additional, Sternberg, Cora N., additional, Vaishampayan, Ulka N., additional, Théodore, Christine, additional, Rosenberg, Jonathan E., additional, Harshman, Lauren C., additional, Bellmunt, Joaquim, additional, Galsky, Matthew D., additional, Gallina, Andrea, additional, Salonia, Andrea, additional, Montorsi, Francesco, additional, and Necchi, Andrea, additional

Published
2019
Full Text
View/download PDF

117. HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition

Author

Jaguva Vasudevan, Ananda Ayyappan, primary, Hoffmann, Michèle J., additional, Beck, Michael L. C., additional, Poschmann, Gereon, additional, Petzsch, Patrick, additional, Wiek, Constanze, additional, Stühler, Kai, additional, Köhrer, Karl, additional, Schulz, Wolfgang A., additional, and Niegisch, Günter, additional

Published
2019
Full Text
View/download PDF

118. Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” [Eur Urol 2018;73:462–8]

Author

Perez-Gracia, Jose Luis, primary, Loriot, Yohann, additional, Rosenberg, Jonathan E., additional, Powles, Thomas, additional, Necchi, Andrea, additional, Hussain, Syed A., additional, Morales-Barrera, Rafael, additional, Retz, Margitta M., additional, Niegisch, Günter, additional, Durán, Ignacio, additional, Théodore, Christine, additional, Grande, Enrique, additional, Shen, Xiaodong, additional, Wang, Jingjing, additional, Nelson, Betty, additional, Derleth, Christina L., additional, and van der Heijden, Michiel S., additional

Published
2019
Full Text
View/download PDF

121. Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

Author

Del Bene, Gabriella, primary, Calabrò, Fabio, additional, Giannarelli, Diana, additional, Plimack, Elizabeth R., additional, Harshman, Lauren C., additional, Yu, Evan Y., additional, Crabb, Simon J., additional, Pal, Sumanta Kumar, additional, Alva, Ajjai S., additional, Powles, Thomas, additional, De Giorgi, Ugo, additional, Agarwal, Neeraj, additional, Bamias, Aristotelis, additional, Ladoire, Sylvain, additional, Necchi, Andrea, additional, Vaishampayan, Ulka N., additional, Niegisch, Günter, additional, Bellmunt, Joaquim, additional, Baniel, Jack, additional, Galsky, Matthew D., additional, and Sternberg, Cora N., additional

Published
2018
Full Text
View/download PDF

124. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex

Author

Schlütermann, David, primary, Skowron, Margaretha A., additional, Berleth, Niklas, additional, Böhler, Philip, additional, Deitersen, Jana, additional, Stuhldreier, Fabian, additional, Wallot-Hieke, Nora, additional, Wu, Wenxian, additional, Peter, Christoph, additional, Hoffmann, Michèle J., additional, Niegisch, Günter, additional, and Stork, Björn, additional

Published
2018
Full Text
View/download PDF

125. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

Author

Perez-Gracia, Jose Luis, primary, Loriot, Yohann, additional, Rosenberg, Jonathan E., additional, Powles, Thomas, additional, Necchi, Andrea, additional, Hussain, Syed A., additional, Morales-Barrera, Rafael, additional, Retz, Margitta M., additional, Niegisch, Günter, additional, Durán, Ignacio, additional, Théodore, Christine, additional, Grande, Enrique, additional, Shen, Xiaodong, additional, Wang, Jingjing, additional, Nelson, Betty, additional, Derleth, Christina L., additional, and van der Heijden, Michiel S., additional

Published
2018
Full Text
View/download PDF

129. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany

Author

Niegisch, Günter, primary, Gerullis, Holger, additional, Lin, Shih-Wen, additional, Pavlova, Julie, additional, Gondos, Adam, additional, Rudolph, Anja, additional, Haas, Gabriele, additional, Hennies, Nora, additional, and Kramer, Mario W., additional

Published
2018
Full Text
View/download PDF

130. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Petrylak, Daniel P, primary, de Wit, Ronald, additional, Chi, Kim N, additional, Drakaki, Alexandra, additional, Sternberg, Cora N, additional, Nishiyama, Hiroyuki, additional, Castellano, Daniel, additional, Hussain, Syed, additional, Fléchon, Aude, additional, Bamias, Aristotelis, additional, Yu, Evan Y, additional, van der Heijden, Michiel S, additional, Matsubara, Nobuaki, additional, Alekseev, Boris, additional, Necchi, Andrea, additional, Géczi, Lajos, additional, Ou, Yen-Chuan, additional, Coskun, Hasan Senol, additional, Su, Wen-Pin, additional, Hegemann, Miriam, additional, Percent, Ivor J, additional, Lee, Jae-Lyun, additional, Tucci, Marcello, additional, Semenov, Andrey, additional, Laestadius, Fredrik, additional, Peer, Avivit, additional, Tortora, Giampaolo, additional, Safina, Sufia, additional, del Muro, Xavier Garcia, additional, Rodriguez-Vida, Alejo, additional, Cicin, Irfan, additional, Harputluoglu, Hakan, additional, Widau, Ryan C, additional, Liepa, Astra M, additional, Walgren, Richard A, additional, Hamid, Oday, additional, Zimmermann, Annamaria H, additional, Bell-McGuinn, Katherine M, additional, Powles, Thomas, additional, Wong, Suet-Lai Shirley, additional, Tan, Thean Hsiang, additional, Hovey, Elizabeth Jane, additional, Clay, Timothy Dudley, additional, Ng, Siobhan Su Wan, additional, Rutten, Annemie, additional, Machiels, Jean-Pascal, additional, Dumez, Herlinde, additional, Cheng, Susanna Yee-Shan, additional, Chi, Kim Nguyen, additional, Ferrario, Cristiano, additional, Sengeloev, Lisa, additional, Jensen, Niels Viggo, additional, Thibault, Constance, additional, Laguerre, Brigitte, additional, Joly, Florence, additional, Flechon, Aude, additional, Culine, Stéphane, additional, Becht, Catherine, additional, Niegisch, Günter, additional, Stöckle, Michael, additional, Grimm, Marc-Oliver, additional, Gakis, Georgios, additional, Schultze-Seemann, Wolfgang, additional, Kalofonos, Haralambos, additional, Mavroudis, Dimitrios, additional, Papandreou, Christos, additional, Karavasilis, Vasilis, additional, Révész, Janos, additional, Geczi, Lajos, additional, Rosenbaum, Eli, additional, Leibowitz-Amit, Raya, additional, Kejzman, Daniel, additional, Sarid, David, additional, Scagliotti, Giorgio Vittorio, additional, Bracarda, Sergio, additional, Massari, Francesco, additional, Osawa, Takahiro, additional, Miyajima, Naoto, additional, Shinohara, Nobuo, additional, Fukuta, Fumimasa, additional, Ohyama, Chikara, additional, Obara, Wataru, additional, Yamashita, Shinichi, additional, Tomita, Yoshihiko, additional, Kawai, Koji, additional, Fukasawa, Satoshi, additional, Oyama, Masafumi, additional, Yonese, Junji, additional, Nagata, Masayoshi, additional, Uemura, Motohide, additional, Nishimura, Kazuo, additional, Kawakita, Mutsushi, additional, Tsunemori, Hiroyuki, additional, Hashine, Katsuyoshi, additional, Inokuchi, Junichi, additional, Yokomizo, Akira, additional, Nagamori, Satoshi, additional, Lee, Hyo Jin, additional, Park, Se Hoon, additional, Rha, Sun Young, additional, Kim, Yu Jung, additional, Lee, Yun-Gyoo, additional, Cortés, Leticia Vazquez, additional, Flores, Claudia Lorena Urzua, additional, Blaisse, Reinoud J B, additional, Erdkamp, Fransiscus L G, additional, Aarts, Maureen J B, additional, Wojcik-Tomaszewska, Joanna, additional, Tomczak, Piotr, additional, Sikora-Kupis, Bozena, additional, Schenker, Michael, additional, Herzal, Alina Amalia, additional, Udrea, Anghel Adrian, additional, Karlov, Petr, additional, Safina, Sufia Z, additional, Fomkin, Roman, additional, Pulido, Enrique Grande, additional, Del Muro, F Xavier García, additional, Mignorance, Juan Ignacio Delgado, additional, Gauna, Daniel Castellano, additional, Rodríguez-Vida, Alejo, additional, Su, Yu-Li, additional, Lin, Chien-Liang, additional, Lin, Chia-Chi, additional, Yeh, Su-Peng, additional, Çiçin, Irfan, additional, Erman, Mustafa, additional, Urun, Yuksel, additional, Golovko, Yurii, additional, Bondarenko, Igor, additional, Sinielnikov, Ivan, additional, Crabb, Simon, additional, Syndikus, Isabel, additional, Huddart, Robert, additional, Sundar, Santhanam, additional, Chowdhury, Simon, additional, Sarwar, Naveed, additional, Flaig, Thomas, additional, Pan, Chong Xian, additional, Petrylak, Daniel, additional, Schwarz, James, additional, Percent, Ivor, additional, Cultrera, Jennifer, additional, Hainsworth, John, additional, Herms, Benjamin, additional, Lawler, William, additional, Lowe, Thomas, additional, Tagawa, Scott, additional, Aragon-Ching, Jeanny, additional, and Vaishampayan, Ulka, additional

Published
2017
Full Text
View/download PDF

141. Additional file 1: Table S1. of Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines

Author

Skowron, Margaretha, Niegisch, Günter, Fritz, Gerhard, Arent, Tanja, Roermund, Joep Van, Romano, Andrea, Albers, Peter, Schulz, Wolfgang, and Hoffmann, Michèle

Abstract

Primer sequences for quantitative real-time-PCR. Sequences of primers (5′-3′) used for quantitative real-time-PCR including length of PCR product and annealing temperature. bp base pair; Fwd Forward; Rev Reverse. (DOC 48 kb)

Published
2015
Full Text
View/download PDF

142. Evaluation of HER2expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

Author

Nini, Alessandro, Hoffmann, Michèle Janine, Lampignano, Rita, große Siemer, Robert, Dalum, Guus, Szarvas, Tibor, Cotarelo, Cristina Lopez, Schulz, Wolfgang Arthur, Niederacher, Dieter, Neubauer, Hans, Stoecklein, Nikolas Hendrik, and Niegisch, Günter

Abstract

Detection of circulating tumor cells (CTC) by techniques based on epithelial cell adhesion molecule (EpCAM) is suboptimal in urothelial carcinoma (UC). As HER2 is thought to be broadly expressed in UC, we explored its utility for CTC detection. HER2 and EpCAM expression was analyzed in 18 UC cell lines (UCCs) by qRT‐PCR, western blot and fluorescence‐activated cell scanning (FACS) and compared to the strongly HER2‐expressing breast cancer cell line SKBR3 and other controls. HER2 expression in UC patient tissues was measured by qRT PCR and correlated with data on survival and risk for metastasis. UCCs with high EpCAM and variable HER2 expression were used for spike‐in experiments in the CellSearch system. Twenty‐one blood samples from 13 metastatic UC patients were analyzed for HER2‐positive CTCs with CellSearch. HER2 mRNA and protein were broadly expressed in UCC, with some heterogeneity, but at least 10‐fold lower than in the HER‐2+ SKBR3 cells. Variations were unrelated to cellular phenotype or clinicopathological characteristics. EpCAM expression was essentially restricted to UCCs with epitheloid phenotypes. Heterogeneity of EpCAM and HER2 expression was observed also in spike‐in experiments. The 7 of 21 blood samples from 6 of 13 patients were enumerated as CTC positive via EpCAM, but only one sample stained weakly positive (1+) for HER2. Detection rate of CTCs by EpCAM in UC is poor, even in metastatic patients. Because of its widespread expression, particularly in patients with high risk of metastasis, detection of HER2 could improve identification of UC CTCs, which is why combined detection using antibodies for EpCAM and HER2 may be beneficial.

Published
2020
Full Text
View/download PDF

150. Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

Author

Niegisch, Günter, primary, Retz, Margitta, additional, Thalgott, Mark, additional, Balabanov, Stefan, additional, Honecker, Friedemann, additional, Ohlmann, Carsten Henning, additional, Stöckle, Michael, additional, Bögemann, Martin, additional, vom Dorp, Frank, additional, Gschwend, Jürgen, additional, Hartmann, Arndt, additional, Ohmann, Christian, additional, and Albers, Peter, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results